Speakers

Expand/Collapse

William Hastings
Exploratory ImmunoOncology Investigator
Novartis Institute of Biomedical Research

Day One

Wednesday 8th May 2019

1:40 pm | Using 3D Models to Investigate Mechanisms of Relieving Suppression of TME

Tim Spicer
Senior Associate Director - Scientific & Molecular Medicine
Scripps Institute

WORKSHOP B

May 7, 2019

8:00 am | The Translational Advancement Of 3D Technologies Towards Precision Oncology Therapies Directed At Pancreas And Brain Tumors

Day Two

Thursday 9th May 2019

1:00 pm | Combined Genetic Analysis and 3D Screening of Approved Drugs Directly on GBM Patient Tumors

Szczepan Baran
Head of Emerging Technologies
Novartis

Day One

Wednesday 8th May 2019

8:40 am | Beyond 3D-Models - Building Confidence in Microphysiological Models at Novartis

Sylvia Boj
Director - Scientific & Group Leader
Hubrecht Organoid Technology

Day Two

Thursday 9th May 2019

9:10 am | Patient-Derived Organoids for development and discovery of Oncology and Immuno-Oncology Drugs

Shane Horman
Research Investigator III
Novartis GNF

Day One

Wednesday 8th May 2019

8:00 am | Chair’s Welcoming Remarks

Day Two

Thursday 9th May 2019

2:00 pm | Summary Panel Discussion - Assessing Where 3D Systems Shine in Discovery

1:30 pm | Industrialized 3D Drug Discovery: Spheroids in 1536-well Format

8:30 am | Chair’s Opening Remarks

Roger Kamm
Professor
MIT

WORKSHOP E

May 7, 2019

3:00 pm | Model Development For Primary & Metastatic Tumors

Day One

Wednesday 8th May 2019

2:10 pm | Panel Discussion: Incorporating the Immune Component - Requirements for IO Models When Mimicking the Microenvironment in a Dish

Monica Gostissa
Head of Pharmacology
Jounce Therapeutics

Day One

Wednesday 8th May 2019

2:10 pm | Panel Discussion: Incorporating the Immune Component - Requirements for IO Models When Mimicking the Microenvironment in a Dish

Mark Paris
Director Translational Biology
Mitra Biotech

Karsten Boehnke
Oncology TME & Translational Research
Eli Lilly and Company

Day Two

Thursday 9th May 2019

9:40 am | Fireside Chat: Are PDO’s The New PDX?

8:40 am | Application of Patient-Derived Organoid Cultures as Preclinical Model Systems for Target Validation & Translational Research

Joseph Charest
Biomedical Solutions Program Manager
Draper

Day One

Wednesday 8th May 2019

12:10 pm | Using Microfluidics to Evaluate Interactions Between Patient-Derived Tissues & Immune Components

Joe Grosso
Senior Lead, Early Clinical
BMS

Day One

Wednesday 8th May 2019

2:10 pm | Panel Discussion: Incorporating the Immune Component - Requirements for IO Models When Mimicking the Microenvironment in a Dish

Elad Katz
Lead Biologist
University of Dundee

WORKSHOP A

May 7, 2019

8:00 am | A Simple Introduction To The Confusing World Of 3D Oncology Models

Dik Van Gent
Professor
Erasmus MC

WORKSHOP D

May 7, 2019

11:30 am | Designing Cancer-Microfluidic Models: Challenges & Considerations

Daniel Harrington
Assistant Professor
The University of Texas Health Science Center

WORKSHOP F

May 7, 2019

3:00 pm | 3D Tumour Engineering to Recapitulate Microenvironment

Chen Zhao
Senior Research Fellow
NIH

Day Two

Thursday 9th May 2019

11:10 am | Using Clearing-Enhanced 3D (Ce3D) to Dissect Tumor Immune Microenvironment

Anita Seshire
Head of Laboratory Cellular Pharmacology & Translational Innovation Platform Oncology
EMD Serono

Day One

Wednesday 8th May 2019

11:40 am | Utilizing Multicellular 3D Models for Preclinical Drug Discovery

Alejandro Amador
Head, Scientific Leader Discovery Biology Automation
GSK

WORKSHOP C

May 7, 2019

11:30 am | Introduction & Overview To 3D High Content Screening Approaches

Day Two

Thursday 9th May 2019

2:00 pm | Summary Panel Discussion - Assessing Where 3D Systems Shine in Discovery

11:30 am | Active-Learning Strategies for High Content Screening to Improve Clinical Relevance of Oncology Therapeutics

9:40 am | Fireside Chat: Are PDO’s The New PDX?

Adam Cohen
Brand Director
Hanson Wade

Day Two

Thursday 9th May 2019

8:35 am | Mastermind Discussion Feedback